Reflections on the Win Ratio With Time-to-Event Outcomes

被引：0
|
作者：
Wittes, Janet [1 ,2 ]
机构：
[1] Florida Atlantic Univ, Boca Raton, FL 33431 USA
[2] Wittes LLC, 2324 Calif St NW, Washington, DC 20008 USA
来源：
CIRCULATION-HEART FAILURE | 2024年 / 17卷 / 09期
关键词：
Editorials; clinical relevance; patient reported outcome measures; probability; CLINICAL-TRIALS;
D O I：
10.1161/CIRCHEARTFAILURE.124.012186
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A Bayesian model for time-to-event data with informative censoring
    Kaciroti, Niko A.
    Raghunathan, Trivellore E.
    Taylor, Jeremy M. G.
    Julius, Stevo
    BIOSTATISTICS, 2012, 13 (02) : 341 - 354
  • [22] An audit strategy for time-to-event outcomes measured with error: Application to five randomized controlled trials in oncology
    Dodd, Lori E.
    Korn, Edward L.
    Freidlin, Boris
    Gu, Wenjuan
    Abrams, Jeffrey S.
    Bushnell, William D.
    Canetta, Renzo
    Doroshow, James H.
    Gray, Robert J.
    Sridhara, Rajeshwari
    CLINICAL TRIALS, 2013, 10 (05) : 754 - 760
  • [23] Restricted mean survival time as a summary measure of time-to-event outcome
    Hasegawa, Takahiro
    Misawa, Saori
    Nakagawa, Shintaro
    Tanaka, Shinichi
    Tanase, Takanori
    Ugai, Hiroyuki
    Wakana, Akira
    Yodo, Yasuhide
    Tsuchiya, Satoru
    Suganami, Hideki
    PHARMACEUTICAL STATISTICS, 2020, 19 (04) : 436 - 453
  • [24] Estimation of win, loss probabilities, and win ratio based on right-censored event data
    Parner, Erik T.
    Overgaard, Morten
    SCANDINAVIAN JOURNAL OF STATISTICS, 2025, 52 (01) : 170 - 184
  • [25] Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
    Gourgou-Bourgade, S.
    Cameron, D.
    Poortmans, P.
    Asselain, B.
    Azria, D.
    Cardoso, F.
    A'Hern, R.
    Bliss, J.
    Bogaerts, J.
    Bonnefoi, H.
    Brain, E.
    Cardoso, M. J.
    Chibaudel, B.
    Coleman, R.
    Cufer, T.
    Dal Lago, L.
    Dalenc, F.
    De Azambuja, E.
    Debled, M.
    Delaloge, S.
    Filleron, T.
    Gligorov, J.
    Gutowski, M.
    Jacot, W.
    Kirkove, C.
    MacGrogan, G.
    Michiels, S.
    Negreiros, I.
    Offersen, B. V.
    Llorca, F. Penault
    Pruneri, G.
    Roche, H.
    Russell, N. S.
    Schmitt, F.
    Servent, V.
    Thuerlimann, B.
    Untch, M.
    van der Hage, J. A.
    van Tienhoven, G.
    Wildiers, H.
    Yarnold, J.
    Bonnetain, F.
    Mathoulin-Pelissier, S.
    Bellera, C.
    Dabakuyo-Yonli, T. S.
    ANNALS OF ONCOLOGY, 2015, 26 (05) : 873 - 879
  • [26] Reporting of loss to follow-up information in randomised controlled trials with time-to-event outcomes: a literature survey
    Vervoelgyi, Elke
    Kromp, Mandy
    Skipka, Guido
    Bender, Ralf
    Kaiser, Thomas
    BMC MEDICAL RESEARCH METHODOLOGY, 2011, 11
  • [27] Investigating the appropriateness of different concordance measures in a time-to-event setting
    Caetano, Samantha-Jo
    Pond, Gregory
    PHARMACEUTICAL STATISTICS, 2020, 19 (06) : 763 - 775
  • [28] Statistical issues in the analysis of adverse events in time-to-event data
    Allignol, Arthur
    Beyersmann, Jan
    Schmoor, Claudia
    PHARMACEUTICAL STATISTICS, 2016, 15 (04) : 297 - 305
  • [29] Reference-based sensitivity analysis for time-to-event data
    Atkinson, Andrew
    Kenward, Michael G.
    Clayton, Tim
    Carpenter, James R.
    PHARMACEUTICAL STATISTICS, 2019, 18 (06) : 645 - 658
  • [30] Adaptive Designs for Two Candidate Primary Time-to-Event Endpoints
    Rauch, Geraldine
    Schuler, Svenja
    Wirths, Marius
    Englert, Stefan
    Kieser, Meinhard
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (02): : 207 - 216
12345